

.....

# Nox Connect

## Connecting People, Data, and Workflows



# Nox Connect

## Connected Sleep Diagnostics for Greater Clinical and Operational Impact

Nox Connect integrates devices, data management, and clinical workflows into a single cloud-based platform that connects teams, simplifies operations, and enables secure access to advanced sleep diagnostic tools.

## Nox Connect connects teams, data, and workflows to support seamless care delivery across in-lab and home studies



## Designed to Support Better Clinical and Operational Outcomes

### Clinical Confidence

AI-enhanced analysis, part of DeepResp, that supports more accurate OSA severity classification, reduces inconclusive and false-negative HSAT results, and helps identify patients who may otherwise remain undiagnosed.<sup>3</sup>

### Operational Efficiency

Reduced scoring time with access to reliable automated analysis, supporting increased throughput, fewer repeat studies, and lower IT complexity with cloud infrastructure.<sup>3</sup>

### Connected Operations

Secure collaboration across technologists, physicians, administrators, and referring providers.

<sup>1</sup> The informational AI tools are not intended for clinical decision-making and are not supported by clinical claims. They are provided for informational purposes only.

<sup>2</sup> Noxturnal Web and DeepResp are CE-marked and FDA cleared software-as-a-medical devices (SaMD). Nox Connect platform is a non-medical device software-as-a-service (SaaS) application. It serves as an interface and may enable access to regulated software-as-a-medical device (SaMD) applications such as DeepResp and Noxturnal Web.

<sup>3</sup> As a result of scoring sleep stages and arousals, in addition to respiratory events, DeepRESP (CE-marked and FDA Cleared SaMD), provides an AHI from HSAT that closely aligns with PSG study. DeepRESP therefore significantly reduces inconclusive or false-negative home sleep studies. Accuracy: 90.6% (AHI ≥ 5) and 81.7% (AHI ≥ 15). Performance based on clinical validation studies included in the clinical evaluation supporting CE marking under EU MDR (2017/745); data also submitted in FDA 510(k) K252330.